Intec Pharma (NTEC) Enters Agreement with Michael J. Fox Foundation to Support Trial Recruitment
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Intec Pharma Ltd. (Nasdaq: NTEC) entered into an agreement with the Michael J. Fox Foundation for Parkinson's Research (MJFF) to support patient recruitment and retention support for the Intec Pharma's pivotal Phase III clinical trial of its lead product candidate, the Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, which began enrolling participants in April 2016.
MJFF is the largest non-profit funder of Parkinson's research with a mission to accelerate the development of new therapies and a cure for Parkinson's disease. Previously, the foundation supported Intec Pharma with a $705,000 grant to fund a pre-clinical study of AP-CD/LD.
"We are honored and pleased to collaborate with the foundation on our Phase III trial recruitment activities," said Zeev Weiss, Intec Pharma's Chief Executive Officer. "MJFF is one of the most well-respected research organizations dedicated to the development of improved therapies for Parkinson's patients. The foundation's long-term experience in the field and close connections with the patient community are especially valuable and will further support and enhance the conduct of our Phase III study for the benefit of the entire patient population."
"Additional options to treat the motor symptoms of Parkinson's would have a significant impact on the millions living with this disease," said Catherine Kopil, PhD, MJFF director of research partnerships. "Leveraging our Foundation's tools and best practices to encourage participant enrollment in Intec Pharma's AP-CD/LD study will accelerate testing of this potential therapy."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Voyager Therapeutics (VYGR) Offers Update on Phase 1b Trial of VY-AADC01 for Advanced Parkinson's Disease
- Concert Pharma (CNCE) CTP-656 Granted FDA Orphan Drug Designation in CF
- Minerva Neurosciences (NERV) Reports Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!